Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland
Thürlimann B. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast cancer (Tokyo, Japan) 2001; 8:294-7.
01.01.2001International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland
01.01.2001Breast cancer (Tokyo, Japan) 2001; 8:294-7
Thürlimann Beat
Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom
Huober J, Meyer A, Wagner U, Wallwiener D. Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom. Med. Welt 2001; 52:101-105.
01.01.2001Primäre Chemotheraphie und Intervalllaparotomie beim fortgeschrittenen Ovarialkarzinom
01.01.2001Med. Welt 2001; 52:101-105
Huober Jens, Meyer A, Wagner U, Wallwiener D
Qualitätssicherung in der operativen Theraphie von Ovarialtumoren
Huober J, Meyer A, Wagner U, Wallwiener D. Qualitätssicherung in der operativen Theraphie von Ovarialtumoren. Med. Welt 2001; 52:184-187.
01.01.2001Qualitätssicherung in der operativen Theraphie von Ovarialtumoren
01.01.2001Med. Welt 2001; 52:184-187
Huober Jens, Meyer A, Wagner U, Wallwiener D
Identifying breast cancer patients at high risk for bone metastases
Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35.
01.12.2000Identifying breast cancer patients at high risk for bone metastases
01.12.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35
Colleoni M, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R D, Bonetti M, Thürlimann Beat, Price K N, Castiglione-Gertsch M, Coates A S, Rudenstam C M
Attitudes and Beliefs towards Disease and Treatment in Patients with Advanced Cancer Using Anthroposophical Medicine
von Rohr E, Pampallona S, van Wegberg B, Cerny T, Hürny C, Bernhard J, Helwig S, Heusser P. Attitudes and Beliefs towards Disease and Treatment in Patients with Advanced Cancer Using Anthroposophical Medicine. Onkologie 2000; 23:558-563.
01.12.2000Attitudes and Beliefs towards Disease and Treatment in Patients with Advanced Cancer Using Anthroposophical Medicine
01.12.2000Onkologie 2000; 23:558-563
von Rohr E., Pampallona S., van Wegberg B., Cerny Thomas, Hürny C., Bernhard J., Helwig S., Heusser P.
Current Status of Dendritic Cell-Based Tumor Vaccination
Dannull J, Cerny T, Ackermann D, Groettrup M. Current Status of Dendritic Cell-Based Tumor Vaccination. Onkologie 2000; 23:544-551.
01.12.2000Current Status of Dendritic Cell-Based Tumor Vaccination
01.12.2000Onkologie 2000; 23:544-551
Dannull J., Cerny Thomas, Ackermann D.K., Groettrup M.
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J, Thürlimann B, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57.
15.11.2000Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
15.11.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J F, Thürlimann Beat, von Euler M
Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer
Huober J, Nakamura S, Meyn R, Roth J, Mukhopadhyay T. Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer. International journal of radiation oncology, biology, physics 2000; 48:1127-37.
01.11.2000Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer
01.11.2000International journal of radiation oncology, biology, physics 2000; 48:1127-37
Huober Jens, Nakamura S, Meyn R, Roth J A, Mukhopadhyay T
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer
Dannull J, Diener P, Prikler L, Fürstenberger G, Cerny T, Schmid U, Ackermann D, Groettrup M. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer research 2000; 60:5522-8.
01.10.2000Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer
01.10.2000Cancer research 2000; 60:5522-8
Dannull J, Diener P A, Prikler L, Fürstenberger G, Cerny Thomas, Schmid U, Ackermann D K, Groettrup M
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
Vergote I, Steinberg M, Webster A, Koralewski L, Mauriac L, Krzakowski M, Robertson J, Thürlimann B, Bonneterre J, von Euler M. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2000; 36 Suppl 4:S84-5.
01.09.2000Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
01.09.2000European journal of cancer (Oxford, England : 1990) 2000; 36 Suppl 4:S84-5
Vergote I, Steinberg M, Webster A, Koralewski L, Mauriac L, Krzakowski M, Robertson J, Thürlimann Beat, Bonneterre J, von Euler M
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
Möhle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000; 110:563-72.
01.09.2000Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
01.09.2000Br J Haematol 2000; 110:563-72
Möhle R, Schittenhelm Marcus, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L
Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer
Von Rohr E, Pampallona S, Van Wegberg B, Hürny C, Bernhard J, Heusser P, Cerny T. Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer. Schweizerische medizinische Wochenschrift 2000; 130:1173-84.
26.08.2000Experiences in the realisation of a research project on anthroposophical medicine in patients with advanced cancer
26.08.2000Schweizerische medizinische Wochenschrift 2000; 130:1173-84
Von Rohr E, Pampallona S, Van Wegberg B, Hürny C, Bernhard J, Heusser P, Cerny Thomas
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91.
01.08.2000Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
01.08.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A
Pneumococcal vaccine in patients with absent or dysfunctional spleen
Kobel D, Friedl A, Cerny T, Mühlemann K. Pneumococcal vaccine in patients with absent or dysfunctional spleen. Mayo Clinic proceedings. Mayo Clinic 2000; 75:749-53.
01.07.2000Pneumococcal vaccine in patients with absent or dysfunctional spleen
01.07.2000Mayo Clinic proceedings. Mayo Clinic 2000; 75:749-53
Kobel D E, Friedl A, Cerny Thomas, Mühlemann K
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand
Mach N, Gillessen Sommer S, Wilson S, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer research 2000; 60:3239-46.
15.06.2000Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand
15.06.2000Cancer research 2000; 60:3239-46
Mach N, Gillessen Sommer Silke, Wilson S B, Sheehan C, Mihm M, Dranoff G
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi S, Coates A, Werner I, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C, Thürlimann B, Collins J, Gelber R, Castiglione-Gertsch M, Gelber S, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet 2000; 355:1869-74.
27.05.2000Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
27.05.2000Lancet 2000; 355:1869-74
Aebi S, Coates A S, Werner I D, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C M, Thürlimann Beat, Collins J, Gelber R D, Castiglione-Gertsch M, Gelber S, Goldhirsch A
Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages
Shi G, Bryant R, Riese R, Verhelst S, Driessen C, Li Z, Bromme D, Ploegh H, Chapman H. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. The Journal of experimental medicine 2000; 191:1177-86.
03.04.2000Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages
03.04.2000The Journal of experimental medicine 2000; 191:1177-86
Shi G P, Bryant R A, Riese R, Verhelst S, Driessen Christoph, Li Z, Bromme D, Ploegh H L, Chapman H A
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII
Crivellari D, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R, Rudenstam C, Thürlimann B, Price K, Coates A, Hürny C, Goldhirsch A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:1412-22.
01.04.2000Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII
01.04.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:1412-22
Crivellari D, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R D, Rudenstam C M, Thürlimann Beat, Price K N, Coates A S, Hürny C, Goldhirsch A
Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM
Villadangos J, Driessen C, Shi G, Chapman H, Ploegh H. Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM. The EMBO journal 2000; 19:882-91.
01.03.2000Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM
01.03.2000The EMBO journal 2000; 19:882-91
Villadangos J A, Driessen Christoph, Shi G P, Chapman H A, Ploegh H L
Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
Gessner U, Köberle D, Thürlimann B, Bacchus L, Horisberger B. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000; 8:115-22.
01.03.2000Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
01.03.2000Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000; 8:115-22
Gessner U, Köberle Dieter, Thürlimann Beat, Bacchus L, Horisberger B